M2 Presswire - Market Commentary on Merck & Co. Inc.
M2 PRESSWIRE-28 June 2007-Biotech News: Market Commentary on Merck & Co. Inc(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:28062007 Market Commentary on Merck & Co. Inc (NYSE:MRK) Merck & Co., Inc. engages in the discovery, development, manufacture, and marketing of various products for human and animal health.
Related Results
Merck & Co’s Cozaar gets US approval for stroke prevention.
Panel adds to uses for drug. (Digest).(Cozaar approved as therapy for reducin…
Merck Reports First-Quarter 2008 Financial Results
Bellwether Report.com is Looking at Merck & Co. Inc.
Hypertensive drug classes: brand names only
It offers Singulair for the chronic treatment of asthma, and relief of symptoms of allergic rhinitis; Cozaar/Hyzaar and Vasotec for the treatment of hypertension/heart failure; Fosamax and Fosamax Plus D for the treatment and prevention of osteoporosis; Zocor, an …
Read the rest of this article with a Free Trial at HighBeam Research.
